Clinical Trial Update: Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial of Nabi-HB given subcutaneously for chronic hepatitis B after liver transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Nabi-HB (hepatitis B immune globulin)

Snippet

Sponsor: Biotest Pharmaceuticals Corporation | Conditions: Hepatitis B, Chronic | Phase 3 | Status: WITHDRAWN